NDAINTRAMUSCULAR, SUBCUTANEOUSSOLUTION
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ZIMHI (naloxone hydrochloride) by R-Pharm US is clinical pharmacology complete or partial reversal of opioid depression naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. First approved in 2021.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIMHI is a naloxone hydrochloride injection approved for rapid reversal of opioid overdose and respiratory depression via intramuscular or subcutaneous routes. It works as a pure opioid antagonist by competitively binding to µ, κ, and σ opioid receptors in the CNS, with highest affinity for the µ receptor. The drug has onset of action within two minutes when administered IV and produces no pharmacologic activity in the absence of opioids.
$0.011BPart D
Peak15.0 years to LOEZIMHI is in peak lifecycle stage with minimal Part D penetration (78 claims in 2023), suggesting early-stage commercialization and growing team investment in market expansion.
Mechanism of Action
CLINICAL PHARMACOLOGY Complete or Partial Reversal of Opioid Depression Naloxone hydrochloride prevents or reverses the effects of opioids including respiratory depression, sedation, and hypotension. Also, naloxone hydrochloride can reverse the psychotomimetic and dysphoric effects of…
Worked on ZIMHI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.